Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm for about $562 million. The portfolio to be offloaded to Cheplapharm is made up of non-core prescription pharma products in a range of therapeutic segments. This includes cardiovascular/metabolic and anti-inflammatory […]
Continue reading …Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates (collectively Blackstone) for JPY 242 billion ($2.3 billion). The business being divested- Takeda Consumer Healthcare Company (TCHC) is focused on the consumer health care market […]
Continue reading …US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]
Continue reading …Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]
Continue reading …Japan-based Takeda Pharmaceutical has agreed to sell a portfolio of 110 non-core over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe along with a couple of manufacturing plants in Denmark and Poland to Orifarm Group for up to $670 million. As per the terms of the deal, Orifarm will pay nearly $505 million to […]
Continue reading …Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth up to $330 million. The Japanese pharma major exercised its option to acquire the US pharma company following the completion of a phase 1 proof-of-mechanism study of the latter’s investigational […]
Continue reading …ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase 3 ALTA-1L trial. The Japanese pharma company released updated data from the late-stage trial involving adult patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who did […]
Continue reading …Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]
Continue reading …ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]
Continue reading …